StockData
Carlsmed, Inc. logo

Carlsmed, Inc. (CARL) company profile

CARLNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30118% above fair value
$17.74+0.39 (+2.25%)

Close on Nov 17, 2026Market cap $484.35MP/E –Yield –

About Carlsmed

Surgical & Medical Instruments & Apparatus, SIC 3841

Carlsmed, Inc. is a medical technology company that develops artificial intelligence-enabled personalized solutions for spine fusion surgery. Its core offering is the aprevo Technology Platform, which integrates digital surgical planning software with custom-designed interbody implants tailored to each patient's specific spinal anatomy, alongside single-use surgical instruments. The platform addresses spinal conditions including degenerative disc disease and adult spinal deformity across both lumbar and cervical fusion procedures. Carlsmed sells its personalized implants and surgical solutions directly to hospitals and ambulatory surgical centers for use by spine surgeons.

Carlsmed focuses its commercial activities within the United States, utilizing a direct sales organization alongside independent sales agents to market its systems. As of December 31, 2025, 253 surgeon users have completed one or more spine fusion procedures using the aprevo platform. The company's corporate headquarters and principal executive offices are located in Carlsbad, California.

Summary of the business section of Carlsmed's latest annual report, written by StockData.

Company profile

Company

Legal name
Carlsmed, Inc.
Headquarters
Carlsbad, CA
Address
1800 Aston Avenue, Suite 100 92008
Phone
(858) 295-9290
Employees
24, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
CARL
Exchange
Nasdaq
IPO date
Jul 24, 2025
Shares outstanding
27M, Aug 3, 2026
Filer category
<br>Emerging growth company
SEC CIK
1794546
CUSIP
14280C105
ISIN
US14280C1053
FIGI
BBG00PQMDFQ1
Share class FIGI
BBG00PQMDFR0
LEI
5299003NUOF1GRY8UX10
EIN
83-1081863

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael CordonnierCEO, President, Director1,517,213
Niall CaseyChief IP Officer, Director982,562
Jeffrey BertoliniChief Operating Officer22,489
Jennifer KamocsayChief Legal Officer56,222
Richard HeppenstallCFO, Treasurer89,286
William Scott DurallChief Commercial Officer44,977
Leonard M. GreensteinCFO, Treasurer188,346
Kevin SidowDirector73,264
Jonathan D. RootDirector716,221
Kevin C. OboyleDirector31,031
Philip M. YoungDirector84,364
Robert Mittendorff IIDirector5,013,839

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Mike Cordonnier
Chief Executive Officer, President and Co-Founder
$480.82K$353.22K$1.51M$414.71K$30.85K$2.79M+436%
Leo Greenstein
Chief Financial Officer and Treasurer
$377.86K–$517.42K$217.27K$6.75K$1.12M+129%
Scott Durall
Chief Commercial Officer
$411.26K–$802.74K$283.77K$18.50K$1.52M+264%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 24, 2025
Offer price
$15.00
Securities offered
6,700,000
Gross proceeds
$100.50M
Exchange
Nasdaq
First trading day
Jul 23, 2025
First-day close
$14.50-3.3%
Lock-up ends (est.)
Jan 19, 2026

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?